Abstract
The presentation titled “TDM in Clinical Trials: Optimizing Therapy and Personalizing Treatment” explores the role of Therapeutic Drug Monitoring (TDM) in enhancing the efficacy and safety of clinical treatments. It emphasizes how TDM supports personalized medicine by adjusting drug dosages based on individual patient variability, including genetic factors, age, and comorbidities. The presentation outlines current challenges in fixed-dose strategies, such as toxicity and suboptimal efficacy, and introduces TDM methodologies, including sample collection, analytical techniques and real-time data interpretation. Case studies from oncology and immunology demonstrate the clinical benefits of TDM, while future directions highlight the integration of data-driven approaches in clinical research.
Dr. Michal Owca, a highly experienced clinical research professional with a strong foundation in project management. I hold an MA in Pharmacy from Jagiellonian University Medical College in Cracow, Poland, and completed postgraduate studies in Medical Business Management at SGH Warsaw School of Economics. I currently serve as a Senior Project Coordinator at a Clinical Trials CRO, with parrarel experience as an academic lecturer in Pharmacology at Jagiellonian University Medical College, and as a registered community pharmacist.
My research interests focus on improving accessibility to biological drugs in oncology. I am an active member of ENOTTA and have made a meaningful impact during the COVID-19 pandemic by qualifying and vaccinating over 5,000 patients.
Outside of work, I’m passionate about traveling, cooking, fitness, hiking, and cycling—and I’m a proud dog dad to Rysiu and Romek.